Curiox China Terminates ₩2.7bn HT and Buffer Exchanger Equipment Sales Contract
Curiox Biosystems filed notice that it terminated an equipment sales contract with its subsidiary Curiox Biosystems China Co., Ltd., effective Oct 29, 2026. The terminated contract amount was ₩2.7bn, reported as 37.6% of revenue. The company stated that it received an official letter from the upstream contractor saying performance of the contract was impossible.
Key facts
| Event | Contract terminated |
|---|---|
| Contract name | HT and Buffer Exchanger equipment sales contract |
| Counterparty | Curiox Biosystems China Co., Ltd. |
| Terminated contract amount | ₩2.7bn |
| % of revenue (as reported) | 37.6% |
| Reason for termination | Received an official letter from the upstream contractor Hunan Deshengyuan Biotechnology Co., Ltd. stating that performance of the contract is impossible |
| Termination date | Oct 29, 2026 |
Comparison
| Amount as % of FY2025 revenue (calculated) | 52.8% |
|---|---|
| Revenue 2025 | ₩5.2bn |
| Revenue 2024 | ₩4.6bn |
| Revenue 2023 | ₩6.8bn |
Context
By our calculation, the terminated contract amount is 52.8% of FY2025 revenue.
Key metrics
Supply contracts
| Supply contracts, last 12 months | ₩0 |
|---|---|
| Supply contracts vs prior-year revenue | 0.0% |
| Contracts without a KRW amount | 0 contracts without a KRW amount excluded |
Source: DART (Financial Supervisory Service) · Original filing on DART ↗